Evidence map›Paper›PMID 41382381›Full record

Observational studyThe Journal of antimicrobial chemotherapy2026

β-Lactam dosing in critically ill children: predictors for target non-attainment.

Stef Schouwenburg, Tim Preijers, Roelie M Wösten-Van Asperen, Enno D Wildschut, Nelianne J Verkaik, Alan Abdulla, Matthijs de Hoog, Birgit C P Koch

Abstract readObservational Study
In one paragraph

Observational study in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stef SchouwenburgDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0003-1835-0749
Tim PreijersDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0001-6953-0358
Roelie M Wösten-Van AsperenDepartment of Pediatric Intensive Care, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Enno D WildschutDepartment of Neonatal and Pediatric Intensive Care, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, The Netherlands.ORCID 0009-0005-5197-2656
Nelianne J VerkaikDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
Alan AbdullaRotterdam Clinical Pharmacometrics Group, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-2158-6376
Matthijs de HoogDepartment of Neonatal and Pediatric Intensive Care, Division of Neonatology, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, The Netherlands.
Birgit C P KochDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-1202-3643

Funding

Erasmus MC
6 · The paper itself

Abstract

introductionβ-Lactam antibiotics are among the most frequently prescribed antibiotics on the paediatric ICU (PICU). For β-lactam antibiotics, unbound plasma concentrations above at least one to four times the MIC for 100% of the dosing interval (100% ƒT > 1-4×MIC) have been proposed as the pharmacodynamic target. This study aimed to determine target attainment of β-lactam antibiotics in PICUs and to identify predictors of target non-attainment. PATIENTS AND

methodsThis prospective observational study was performed in two PICUs in the Netherlands. We enrolled paediatric patients treated with the following β-lactam antibiotics: cefotaxime, ceftazidime, ceftriaxone, cefuroxime, flucloxacillin and meropenem. The free concentration above the bacterial epidemiological cut-off minimum inhibitory concentration (ƒT > MICECOFF and ƒT > 4×MICECOFF) was determined. Secondary endpoints were estimated regression models for examining the association of target non-attainment with patient characteristics and clinical outcomes.

resultsA total of 116 patients were included, of whom 27.6% achieved 100% ƒT > MICECOFF and 13.7% achieved 100% ƒT > 4×MICECOFF. Regression analysis identified an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m2 as a risk factor for target non-attainment. In addition, no significant association between the 100% ƒT > MICECOFF target attainment and ICU length of stay (LOS) was found. However, for both pharmacodynamic targets, a significant correlation was found between LOS and age in years.

conclusionsThis study found an eGFR ≥90 mL/min/1.73 m2 to be associated with target non-attainment, indicating that kidney function should be taken into account when identifying individuals who may require higher dosages. These results may help identify subpopulations of paediatric patients requiring higher dosages or continuous infusion in order to achieve adequate β-lactam exposure.

Indexed as

Anti-Bacterial Agentsbeta-LactamsCritical IllnessAdolescentChildChild, PreschoolFemaleGlomerular Filtration RateHumansInfantIntensive Care Units, PediatricMaleMicrobial Sensitivity TestsNetherlandsProspective StudiesAnti-Bacterial Agentsbeta-Lactams

Identifiers

PMID41382381
PMCPMC12802960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.